Further studies measuring Aβ, tau and GFAP biomarkers at multiple time points with long follow-up durations are needed to confirm the temporal order of appearance of each biomarker abnormality and to determine other possible factors associated with early astrocyte reactivity in preclinical AD. The gene discussed is GFAP; the disease is Alzheimer disease.